Revenue Acceleration LLC
Go-to-market engineering for products that are hard to buy. We prove demand first, then engineer revenue, for the teams bringing consequential medical technology to market, medical devices and diagnostics first.
A hospital, a payer or a pharma buyer cannot say yes until clinical, regulatory, security, legal and finance each have what they need. A normal sales team cannot produce that, and a normal agency does not know it exists. Revenue Acceleration makes a product's evidence and its path to a signed contract ready to survive that committee.
It is the commercial counterpart to Netspective. Netspective helps build solutions that survive regulators; Revenue Acceleration helps sell them, starting with our own. It sells the Demand Engineering AI Workforce™ to companies that have not yet shown a buyer will pay, and the Revenue Engineering AI Workforce™ to those that have, each as bounded offers with a stated scope, outputs and stopping condition. It does not take open-ended custom work.
The method is the one in our books and research on discovery, readiness and discoverability, applied to a buyer's real purchasing path. We start with medical technology, and biotechnology follows. Regulated technology is the common thread across both, not a separate market.
Revenue Acceleration has operated since 2018. Its former revenue-cycle and denial-management service for home-based care moves into the Physia Platform, and revenue.health forwards to Physia from 1 January 2027.